This page is for informational purposes only. It is not medical advice. Talk to your doctor before starting, changing, or stopping any medication.

This page contains affiliate links. We earn a commission when you click through and purchase. This does not change our editorial rankings or opinions.

Ozempic vs Mounjaro (2026)

Quick answer

Ozempic is semaglutide, approved for type 2 diabetes. Mounjaro is tirzepatide, also approved for type 2 diabetes. Both cause significant weight loss as a side effect. Clinical data shows Mounjaro achieves greater average weight loss. Both require a prescription and physician oversight.

Ozempic vs Mounjaro: Side-by-Side

FeatureOzempicMounjaro
Active ingredientSemaglutideTirzepatide
MechanismGLP-1 agonistGIP + GLP-1 dual agonist
Max dose2 mg/week15 mg/week
Avg HbA1c reduction1.8%2.07%
Avg weight loss12-15 lbs~25 lbs
Cost without insurance~$935/mo~$1,060/mo
Savings program$25/mo co-pay (eligible)$25/mo co-pay (eligible)

Important: Ozempic and Mounjaro are both FDA-approved for type 2 diabetes, not weight loss. The weight loss versions of these drugs are Wegovy (semaglutide) and Zepbound (tirzepatide) respectively. Off-label prescribing for weight loss is common but insurance coverage is much harder to obtain without a diabetes diagnosis.

Clinical Comparison

No single large head-to-head trial has directly compared Ozempic and Mounjaro in the diabetes population as of mid-2025. SURPASS-CVOT studied Mounjaro versus placebo in high cardiovascular risk patients. Indirect comparisons across the SUSTAIN (Ozempic) and SURPASS (Mounjaro) programs consistently show tirzepatide producing greater weight loss and HbA1c reductions.

Mounjaro's dual GIP and GLP-1 mechanism is the likely driver of its advantage. GLP-1 reduces appetite and slows gastric emptying. GIP adds complementary effects on fat metabolism and further appetite suppression. The combination appears to be additive.

Which Should You Choose?

The best choice between Ozempic and Mounjaro depends on:

Both are excellent drugs for type 2 diabetes management. The weight loss advantage of Mounjaro is meaningful but does not make Ozempic a poor choice if it is better covered by your insurance.

How to Access Ozempic or Mounjaro

Both require a prescription from a licensed physician. Traditional endocrinology appointments can have long wait times. Telehealth platforms that specialize in GLP-1 medications can evaluate and prescribe for eligible patients with shorter wait times.

Eligibility typically requires a type 2 diabetes diagnosis or relevant metabolic markers. The physician reviews your health history and prescribes the appropriate drug and starting dose.

Frequently Asked Questions

Is Mounjaro stronger than Ozempic?

Clinical trial data shows Mounjaro produces greater average weight loss and HbA1c reduction than Ozempic. Mounjaro uses dual GIP and GLP-1 receptor activation, while Ozempic is a GLP-1 agonist only. Head-to-head trials in the diabetes population are limited, but indirect comparisons favor tirzepatide (Mounjaro) for both blood sugar control and weight loss. Talk to your doctor.

Can you take Ozempic and Mounjaro at the same time?

No. Ozempic and Mounjaro both activate GLP-1 receptors. Taking them together is not recommended and has not been studied. The combination would be expected to increase the risk of side effects, including low blood sugar, nausea, and vomiting, without a proven additional benefit. Never take two GLP-1 or dual agonist drugs simultaneously without explicit physician guidance.

Does insurance cover Ozempic and Mounjaro?

Both are FDA-approved for type 2 diabetes and are more commonly covered by insurance for that indication. Coverage for off-label weight loss use is much harder to obtain. With insurance and a diabetes diagnosis, manufacturer savings cards can bring costs down to $25 per month. Without insurance, both cost between $935 and $1,060 per month at retail.

What is the difference between Mounjaro and Zepbound?

Mounjaro and Zepbound contain the same active ingredient: tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The formulations are identical. The difference is the labeled indication, which affects insurance coverage and the prescribing rationale your doctor uses.

Choosing between Ozempic and Mounjaro is a decision for you and your doctor. Your insurance formulary, health history, and diabetes management goals all factor into the best choice. Talk to your doctor before starting, changing, or stopping any medication.

Related Pages